Efficacy and Safety of HD-6277, a Novel GPR40 Agonist, in Patients with Type 2 Diabetes-A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Trial

被引：0
|
作者：
Lee, Yong-Ho
Min, Kyungwan
Hong, Jun Hwa
Lim, Soo
Yu, Jaemyung
Chung, Choon H.
Moon, Jun Sung
Won, Jong Chul
Ahn, Chul Woo
Lee, Jie-Eun
Kim, Tae Nyun
Lee, Byung-Wan
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-853-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
853-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of HD-6277, a Potent and Selective G-Protein-Coupled Receptor 40 (GPR40) Agonist, in Patients with Type 2 Diabetes Mellitus
    Kim, Ki-Hwan
    Yang, Hye-Jung
    Baek, Myoungki
    DIABETES, 2020, 69
  • [2] Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes-A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
    Liu, Lin
    Shi, Xiaoxia
    He, Fei
    Cheng, Zhifeng
    Song, Weihong
    Wang, Zhongjing
    Cui, Yimin
    Zhang, Junqing
    DIABETES, 2024, 73
  • [3] Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
    Dubourg, Julie
    Fouqueray, Pascale
    Thang, Carole
    Grouin, Jean-Marie
    Ueki, Kohjiro
    DIABETES CARE, 2021, 44 (04) : 952 - 959
  • [4] Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
    Venhoff, Nils
    Schmidt, Wolfgang
    Bergner, Raoul
    Rech, Juergen
    Unger, Leonore
    Tony, Hans-Peter
    Mendelson, Meryl
    Sieder, Christian
    Maricos, Meron
    Thiel, Jens
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 4130 - 4133
  • [5] Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Zhang, Bo
    Cheng, Zhifeng
    Chen, Ji
    Zhang, Xin
    Liu, Dexue
    Jiang, Hongwei
    Ma, Guoqing
    Wang, Xiaoyun
    Gan, Shenglian
    Sun, Juan
    Jin, Ping
    Yi, Jianjun
    Shi, Bimin
    Ma, Jianhua
    Ye, Shandong
    Wang, Guixia
    Ji, Linong
    Gu, Xuejiang
    Yu, Ting
    An, Pei
    Deng, Huan
    Li, Haoyu
    Li, Li
    Ma, Qingyang
    Qian, Lei
    Yang, Wenying
    DIABETES CARE, 2024, 47 (01) : 160 - 168
  • [6] A novel GPR40 agonist HD-6277 comparison to Fasiglifam and LY2922470 in type 2 diabetic rats
    Kim, C.
    Kim, Y. -S.
    Yang, G.
    Kang, S.
    Lee, S.
    Choi, H. -S.
    Kim, D. -Y.
    Yoo, H. -E.
    Yang, J.
    Rhee, J. -K.
    Kim, D. -H.
    DIABETOLOGIA, 2017, 60 : S392 - S392
  • [7] Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study
    Li, Yanpeng
    Zhang, Ruoxi
    Zhou, Yanling
    Bao, Cungang
    Lin, Zhaocun
    Chen, Chunyan
    He, Jingjing
    Jin, Zhiping
    Song, Lihua
    Zhang, Min
    Guo, Sigen
    Jiang, Yu
    Zhao, Zhongxin
    SLEEP, 2024, 47 (02)
  • [8] A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil W.
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas L.
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Chin, Peter
    Garren, Hideki
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 17 - 17
  • [9] Efficacy and Safety of Bempedoic Acid for Hypercholesterolemia in Japan: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Trial
    Yamashita, Shizuya
    Fujita, Hitomi
    Yokota, Daisuke
    Morikawa-Isogai, Yuki
    Kitamoto, Ryuki
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2025,
  • [10] EFFICACY AND SAFETY OF GLUCOLO PLUS IN TYPE 2 DIABETES MANAGEMENT (GLEEN STUDY): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL.
    Zarruk, A.
    Zarruk, R.
    Pagnota, V.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A177 - A177
12345